Neurometrix Inc (NURO) 1.78 $NURO
NeuroMetrix to Exhibit at International Meeting
Business Wire - Wed May 07, 8:56AM CDT
NeuroMetrix, Inc. (Nasdaq: NURO), an innovative health care company that develops wearable medical technology and point-of-care tests to help patients and physicians manage chronic pain, nerve diseases, and sleep disorders, reported today that it will be an exhibitor and sponsor at the 15th Malvern Diabetic Foot Conference May 14-16, 2014 in Malvern, United Kingdom, at the Malvern Theatres.
What Makes Vascular Solutions (VASC) a Strong Sell? - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Fri May 02, 7:54AM CDT
Vascular Solutions (VASC) has witnessed a significant price decline in the past four weeks, and it has seen negative earnings estimate revisions for the current quarter as well as the current year.
NeuroMetrix and SENSUS Pain Management System Spotlighted In Media Outlets and Patient Interviews
Business Wire - Tue Apr 29, 10:09AM CDT
NeuroMetrix, Inc. (Nasdaq: NURO), an innovative health care company that develops wearable medical technology and point-of-care tests to help patients and physicians manage chronic pain, nerve diseases, and sleep disorders, has been featured in several media outlets and in patient interviews.
NeuroMetrix Reports First Quarter 2014 Financial Results and Business Highlights
Business Wire - Thu Apr 24, 6:00AM CDT
--Launch of second generation SENSUS device
NeuroMetrix, Inc. Announces Date for 2014 First Quarter Financial Results Conference Call
Business Wire - Wed Apr 16, 10:24AM CDT
NeuroMetrix, Inc. (the "Company"
(Nasdaq: NURO), an innovative health care company that develops wearable medical technology and point-of-care tests to help patients and physicians manage chronic pain, nerve diseases, and sleep disturbances, today said it plans to issue its 2014 first quarter financial results before the opening of the market on April 24, 2014. The Company will host a conference call at 8:00 a.m., Eastern Time on April 24, 2014 to discuss its financial results as well as business developments affecting the Company.
Direct Global Media Re-Initiates Coverage on EKO International (EKNL) and Provides Additional Update on the Cannabis and Medical Marijuana Featured Company HEMP Inc. (HEMP)
Marketwire - Mon Apr 14, 8:02AM CDT
Direct Global Media gives shareholders valuable insight on their feature Medical Technology Company EKO International Corp. (EKNL) and provides further update on their featured Cannabis and Medical Marijuana Company, HEMP Inc. (HEMP)
NeuroMetrix Initiates Patient-Focused Program for Early Detection of Diabetic Peripheral Neuropathy by Podiatrists
Business Wire - Tue Apr 01, 10:21AM CDT
NeuroMetrix, Inc. (the "Company" (Nasdaq: NURO), an innovative health care company that develops wearable medical technology and point-of-care diagnostics that helps patients and physicians better manage chronic pain, nerve disorders, and associated sleep disturbances, today announced an initiative to improve the detection and awareness of diabetic peripheral neuropathy, or DPN, at a reasonable cost to patients. The program is targeted at podiatric physicians and offers creative commercial terms to incorporate a DPN screening program into their clinical practice with NC-stat(R) DPNCheck(R) technology. This objective test will allow them to more accurately assess their patients with diabetes for DPN and enhance the podiatric care they provide.
5 Stocks Under $10 Set to Soar
at The Street - Thu Mar 20, 1:26PM CDT
These under-$10 stocks look ready to trade higher from current levels.
NeuroMetrix Launches Second Generation SENSUS Device
Business Wire - Tue Mar 18, 10:03AM CDT
NeuroMetrix, Inc. (the "Company" (Nasdaq:NURO), an innovative health care company that develops wearable medical technology and point-of-care diagnostics that help patients and physicians better manage chronic pain, nerve disorders, and associated sleep disturbances, today reported first shipments of the second generation of its wearable therapeutic technology, the SENSUS(TM) Pain Management System.
NeuroMetrix Submits Regulatory Application for NC-stat DPNCheck in Japan
Business Wire - Tue Mar 11, 1:45PM CDT
NeuroMetrix, Inc. (Nasdaq: NURO), a medical device company focused on the treatment and management of the neurological complications of diabetes, reported the regulatory submission for NC-stat DPNCheck(R) in Japan. NC-stat DPNCheck is a rapid, accurate and quantitative point-of-care test to detect diabetic peripheral neuropathy, or DPN, at an early stage allowing physicians to select appropriate treatment. DPN is the most common complication of diabetes, affecting over half of people with diabetes. DPN causes significant morbidity including pain, increased risk of falling in the elderly, and is the primary trigger for diabetic foot ulcers which may require lower extremity amputations.
NeuroMetrix CEO Dr. Shai N. Gozani Interviewed Live on TuDiabetes.org
Business Wire - Fri Mar 07, 12:33PM CST
Shai N. Gozani, M.D., Ph.D, President and Chief Executive Officer of NeuroMetrix, Inc. (Nasdaq: NURO), a medical device company focused on the treatment and management of the neurological complications of diabetes, was interviewed live on the TuDiabetes.org website yesterday, March 6, 2014. TuDiabetes.org is a community of people touched by diabetes and is a program of the Diabetes Hands Foundation.
NeuroMetrix Reports Publication of Study Demonstrating that NC-stat DPNCheck is Effective at Detecting Diabetic Peripheral Neuropathy
Business Wire - Mon Mar 03, 11:08AM CST
NeuroMetrix, Inc. (the "Company" (Nasdaq: NURO), a medical device company focused on the treatment and management of the neurological complications of diabetes, today reported publication of results from a study conducted at the University of Toronto. The study by Lee and colleagues titled "Reliability and Validity of a Point-of-Care Sural Nerve Conduction Device for Identification of Diabetic Neuropathy" is available at:
NeuroMetrix Reports Q4 and Full Year 2013 Results
Business Wire - Thu Feb 13, 6:00AM CST
NeuroMetrix, Inc. (the "Company" (Nasdaq: NURO), a medical device company that develops and markets home use and point-of-care devices for the treatment and management of chronic pain, peripheral neuropathies, and associated neurological disorders, today reported business and financial highlights for the fourth quarter and year ended December 31, 2013.
NeuroMetrix, Inc. Announces Date for 2013 Full Year and Fourth Quarter Financial Results Conference Call
Business Wire - Wed Feb 05, 6:00AM CST
NeuroMetrix, Inc. (the "Company" (Nasdaq: NURO), a medical device company focused on the treatment and management of the neurological complications of diabetes, today said it plans to issue its 2013 full year and fourth quarter financial results before the opening of the market on February 13, 2014. The Company will host a conference call at 8:00 a.m., Eastern Time on February 13, 2014 to discuss its financial results as well as business developments affecting the Company.
NeuroMetrix Announces Broad SENSUS Distribution Agreement with DJO Global
Business Wire - Tue Feb 04, 6:00AM CST
NeuroMetrix, Inc. (the "Company" (Nasdaq: NURO), a medical device company focused on the treatment and management of the neurological complications of diabetes, today announced a national distribution agreement with DJO Global for the SENSUS(TM) Pain Management System. SENSUS is a convenient and wearable non-invasive electrical nerve stimulator that offers patients a fast-acting, non-narcotic option for relief from chronic pain. The device is lightweight and can be worn during the day while remaining active, or at night while sleeping. It is optimally designed for people with diabetes that suffer from chronic pain. The most common cause of such pain is painful diabetic neuropathy (PDN), which affects up to 5 million people in the U.S. alone.
NeuroMetrix Launches www.DPNCheck.com To Support Growing NC-stat DPNCheck Business
Business Wire - Mon Jan 27, 6:00AM CST
NeuroMetrix, Inc. (the "Company" (Nasdaq:NURO), a medical device company focused on the treatment and management of the neurological complications of diabetes, today announced the launch of www.DPNCheck.com. The website is an important online resource that will help support the growing domestic and international DPNCheck(R) business. DPNCheck is a fast, accurate and quantitative point-of-care test for diabetic peripheral neuropathy, or DPN. The DPNCheck test addresses an unmet medical need for better and more cost-effective screening, diagnosing and monitoring of DPN. This complication affects over 50% of people with diabetes and leads to foot ulcers and limb amputation, as well as severe pain and an overall reduction in patient quality of life.
NeuroMetrix and SENSUS Pain Management System Spotlighted in Several Media Outlets
Business Wire - Wed Jan 22, 12:21PM CST
NeuroMetrix, Inc. (the "Company" (Nasdaq: NURO), a medical device company focused on the treatment and management of the neurological complications of diabetes, has been featured in several media outlets that spotlighted the Company and the SENSUS(TM) Pain Management System. SENSUS is a convenient and wearable non-invasive electrical nerve stimulator that offers patients a fast-acting, non-narcotic option for relief from chronic pain. The device is lightweight and can be worn during the day while remaining active, or at night while sleeping. It is optimally designed for people with diabetes that suffer from chronic pain. The most common cause of such pain is painful diabetic neuropathy (PDN), which affects up to five million people in the U.S. alone.
Jiro Nakamura M.D., Ph.D. Joins NeuroMetrix Scientific Advisory Board
Business Wire - Thu Jan 16, 10:25AM CST
NeuroMetrix, Inc. (the "Company" (Nasdaq: NURO), a medical device company focused on the treatment and management of the neurological complications of diabetes, today announced that Jiro Nakamura, M.D., Ph.D., has joined its Scientific Advisory Board. Dr. Nakamura is Professor, Division of Diabetes, Department of Internal Medicine, Diabetes Center at the Aichi Medical University School of Medicine in Nagakute, Japan.
NeuroMetrix Previews Selected Highlights of Q4 2013
Business Wire - Mon Jan 13, 5:59AM CST
NeuroMetrix, Inc. (the "Company" (Nasdaq: NURO), a medical device company focused on the treatment and management of the neurological complications of diabetes, today previewed its unaudited financial highlights for the fourth quarter ended December 31, 2013.
Stock to Watch: Neurometrix Up 19.0% (NURO)
Comtex SmarTrend(R) - Tue Dec 10, 10:12AM CST
Neurometrix (NASDAQ:NURO) is one of today's best performing low-priced stocks, up 19.0% to $3.57 on 5.8x average daily volume. Thus far today, Neurometrix has traded 6.2 million shares, vs. average volume of 1.1 million shares per day. The stock has outperformed the Dow (19.0% to the Dow's -0.2%) and outperformed the S&P 500 (19.0% to the S&P's -0.1%) during today's trading.
NeuroMetrix to Exhibit at International Meeting
Business Wire - Wed May 07, 8:56AM CDT
NeuroMetrix, Inc. (Nasdaq: NURO), an innovative health care company that develops wearable medical technology and point-of-care tests to help patients and physicians manage chronic pain, nerve diseases, and sleep disorders, reported today that it will be an exhibitor and sponsor at the 15th Malvern Diabetic Foot Conference May 14-16, 2014 in Malvern, United Kingdom, at the Malvern Theatres.
What Makes Vascular Solutions (VASC) a Strong Sell? - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Fri May 02, 7:54AM CDT
Vascular Solutions (VASC) has witnessed a significant price decline in the past four weeks, and it has seen negative earnings estimate revisions for the current quarter as well as the current year.
NeuroMetrix and SENSUS Pain Management System Spotlighted In Media Outlets and Patient Interviews
Business Wire - Tue Apr 29, 10:09AM CDT
NeuroMetrix, Inc. (Nasdaq: NURO), an innovative health care company that develops wearable medical technology and point-of-care tests to help patients and physicians manage chronic pain, nerve diseases, and sleep disorders, has been featured in several media outlets and in patient interviews.
NeuroMetrix Reports First Quarter 2014 Financial Results and Business Highlights
Business Wire - Thu Apr 24, 6:00AM CDT
--Launch of second generation SENSUS device
NeuroMetrix, Inc. Announces Date for 2014 First Quarter Financial Results Conference Call
Business Wire - Wed Apr 16, 10:24AM CDT
NeuroMetrix, Inc. (the "Company"
(Nasdaq: NURO), an innovative health care company that develops wearable medical technology and point-of-care tests to help patients and physicians manage chronic pain, nerve diseases, and sleep disturbances, today said it plans to issue its 2014 first quarter financial results before the opening of the market on April 24, 2014. The Company will host a conference call at 8:00 a.m., Eastern Time on April 24, 2014 to discuss its financial results as well as business developments affecting the Company. Direct Global Media Re-Initiates Coverage on EKO International (EKNL) and Provides Additional Update on the Cannabis and Medical Marijuana Featured Company HEMP Inc. (HEMP)
Marketwire - Mon Apr 14, 8:02AM CDT
Direct Global Media gives shareholders valuable insight on their feature Medical Technology Company EKO International Corp. (EKNL) and provides further update on their featured Cannabis and Medical Marijuana Company, HEMP Inc. (HEMP)
NeuroMetrix Initiates Patient-Focused Program for Early Detection of Diabetic Peripheral Neuropathy by Podiatrists
Business Wire - Tue Apr 01, 10:21AM CDT
NeuroMetrix, Inc. (the "Company"
(Nasdaq: NURO), an innovative health care company that develops wearable medical technology and point-of-care diagnostics that helps patients and physicians better manage chronic pain, nerve disorders, and associated sleep disturbances, today announced an initiative to improve the detection and awareness of diabetic peripheral neuropathy, or DPN, at a reasonable cost to patients. The program is targeted at podiatric physicians and offers creative commercial terms to incorporate a DPN screening program into their clinical practice with NC-stat(R) DPNCheck(R) technology. This objective test will allow them to more accurately assess their patients with diabetes for DPN and enhance the podiatric care they provide. 5 Stocks Under $10 Set to Soar
at The Street - Thu Mar 20, 1:26PM CDT
These under-$10 stocks look ready to trade higher from current levels.
NeuroMetrix Launches Second Generation SENSUS Device
Business Wire - Tue Mar 18, 10:03AM CDT
NeuroMetrix, Inc. (the "Company"
(Nasdaq:NURO), an innovative health care company that develops wearable medical technology and point-of-care diagnostics that help patients and physicians better manage chronic pain, nerve disorders, and associated sleep disturbances, today reported first shipments of the second generation of its wearable therapeutic technology, the SENSUS(TM) Pain Management System. NeuroMetrix Submits Regulatory Application for NC-stat DPNCheck in Japan
Business Wire - Tue Mar 11, 1:45PM CDT
NeuroMetrix, Inc. (Nasdaq: NURO), a medical device company focused on the treatment and management of the neurological complications of diabetes, reported the regulatory submission for NC-stat DPNCheck(R) in Japan. NC-stat DPNCheck is a rapid, accurate and quantitative point-of-care test to detect diabetic peripheral neuropathy, or DPN, at an early stage allowing physicians to select appropriate treatment. DPN is the most common complication of diabetes, affecting over half of people with diabetes. DPN causes significant morbidity including pain, increased risk of falling in the elderly, and is the primary trigger for diabetic foot ulcers which may require lower extremity amputations.
NeuroMetrix CEO Dr. Shai N. Gozani Interviewed Live on TuDiabetes.org
Business Wire - Fri Mar 07, 12:33PM CST
Shai N. Gozani, M.D., Ph.D, President and Chief Executive Officer of NeuroMetrix, Inc. (Nasdaq: NURO), a medical device company focused on the treatment and management of the neurological complications of diabetes, was interviewed live on the TuDiabetes.org website yesterday, March 6, 2014. TuDiabetes.org is a community of people touched by diabetes and is a program of the Diabetes Hands Foundation.
NeuroMetrix Reports Publication of Study Demonstrating that NC-stat DPNCheck is Effective at Detecting Diabetic Peripheral Neuropathy
Business Wire - Mon Mar 03, 11:08AM CST
NeuroMetrix, Inc. (the "Company"
(Nasdaq: NURO), a medical device company focused on the treatment and management of the neurological complications of diabetes, today reported publication of results from a study conducted at the University of Toronto. The study by Lee and colleagues titled "Reliability and Validity of a Point-of-Care Sural Nerve Conduction Device for Identification of Diabetic Neuropathy" is available at: NeuroMetrix Reports Q4 and Full Year 2013 Results
Business Wire - Thu Feb 13, 6:00AM CST
NeuroMetrix, Inc. (the "Company"
(Nasdaq: NURO), a medical device company that develops and markets home use and point-of-care devices for the treatment and management of chronic pain, peripheral neuropathies, and associated neurological disorders, today reported business and financial highlights for the fourth quarter and year ended December 31, 2013. NeuroMetrix, Inc. Announces Date for 2013 Full Year and Fourth Quarter Financial Results Conference Call
Business Wire - Wed Feb 05, 6:00AM CST
NeuroMetrix, Inc. (the "Company"
(Nasdaq: NURO), a medical device company focused on the treatment and management of the neurological complications of diabetes, today said it plans to issue its 2013 full year and fourth quarter financial results before the opening of the market on February 13, 2014. The Company will host a conference call at 8:00 a.m., Eastern Time on February 13, 2014 to discuss its financial results as well as business developments affecting the Company. NeuroMetrix Announces Broad SENSUS Distribution Agreement with DJO Global
Business Wire - Tue Feb 04, 6:00AM CST
NeuroMetrix, Inc. (the "Company"
(Nasdaq: NURO), a medical device company focused on the treatment and management of the neurological complications of diabetes, today announced a national distribution agreement with DJO Global for the SENSUS(TM) Pain Management System. SENSUS is a convenient and wearable non-invasive electrical nerve stimulator that offers patients a fast-acting, non-narcotic option for relief from chronic pain. The device is lightweight and can be worn during the day while remaining active, or at night while sleeping. It is optimally designed for people with diabetes that suffer from chronic pain. The most common cause of such pain is painful diabetic neuropathy (PDN), which affects up to 5 million people in the U.S. alone. NeuroMetrix Launches www.DPNCheck.com To Support Growing NC-stat DPNCheck Business
Business Wire - Mon Jan 27, 6:00AM CST
NeuroMetrix, Inc. (the "Company"
(Nasdaq:NURO), a medical device company focused on the treatment and management of the neurological complications of diabetes, today announced the launch of www.DPNCheck.com. The website is an important online resource that will help support the growing domestic and international DPNCheck(R) business. DPNCheck is a fast, accurate and quantitative point-of-care test for diabetic peripheral neuropathy, or DPN. The DPNCheck test addresses an unmet medical need for better and more cost-effective screening, diagnosing and monitoring of DPN. This complication affects over 50% of people with diabetes and leads to foot ulcers and limb amputation, as well as severe pain and an overall reduction in patient quality of life. NeuroMetrix and SENSUS Pain Management System Spotlighted in Several Media Outlets
Business Wire - Wed Jan 22, 12:21PM CST
NeuroMetrix, Inc. (the "Company"
(Nasdaq: NURO), a medical device company focused on the treatment and management of the neurological complications of diabetes, has been featured in several media outlets that spotlighted the Company and the SENSUS(TM) Pain Management System. SENSUS is a convenient and wearable non-invasive electrical nerve stimulator that offers patients a fast-acting, non-narcotic option for relief from chronic pain. The device is lightweight and can be worn during the day while remaining active, or at night while sleeping. It is optimally designed for people with diabetes that suffer from chronic pain. The most common cause of such pain is painful diabetic neuropathy (PDN), which affects up to five million people in the U.S. alone. Jiro Nakamura M.D., Ph.D. Joins NeuroMetrix Scientific Advisory Board
Business Wire - Thu Jan 16, 10:25AM CST
NeuroMetrix, Inc. (the "Company"
(Nasdaq: NURO), a medical device company focused on the treatment and management of the neurological complications of diabetes, today announced that Jiro Nakamura, M.D., Ph.D., has joined its Scientific Advisory Board. Dr. Nakamura is Professor, Division of Diabetes, Department of Internal Medicine, Diabetes Center at the Aichi Medical University School of Medicine in Nagakute, Japan. NeuroMetrix Previews Selected Highlights of Q4 2013
Business Wire - Mon Jan 13, 5:59AM CST
NeuroMetrix, Inc. (the "Company"
(Nasdaq: NURO), a medical device company focused on the treatment and management of the neurological complications of diabetes, today previewed its unaudited financial highlights for the fourth quarter ended December 31, 2013. Stock to Watch: Neurometrix Up 19.0% (NURO)
Comtex SmarTrend(R) - Tue Dec 10, 10:12AM CST
Neurometrix (NASDAQ:NURO) is one of today's best performing low-priced stocks, up 19.0% to $3.57 on 5.8x average daily volume. Thus far today, Neurometrix has traded 6.2 million shares, vs. average volume of 1.1 million shares per day. The stock has outperformed the Dow (19.0% to the Dow's -0.2%) and outperformed the S&P 500 (19.0% to the S&P's -0.1%) during today's trading.
